Chondrial Therapeutics: Montco biopharm firm merging with Boston drug developer, creating new public company

Bala Cynwyd-based Chondrial Therapeutics has entered into a definitive merger agreement with Boston biopharmaceutical company Zafgen. The deal, expected to be completed during the first half of 2020, will result in the formation of a new publicly traded company, Larimar Therapeutics, that will be based in Bala Cynwyd. Chondrial stockholders will be issued stock through a private placement and own about 60% of Larimar. Zafgen's (NASDAQ: ZFGN) stockholders will own the remaining 40%. Dr. Carole...